CYP17A1 inhibitors in castration-resistant prostate cancer
about
CYP17 inhibitors in prostate cancer: latest evidence and clinical potentialTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerPromising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 InhibitorsComparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Antioxidants Abrogate Alpha-Tocopherylquinone-Mediated Down-Regulation of the Androgen Receptor in Androgen-Responsive Prostate Cancer Cells.Unveiling the crucial intermediates in androgen production.Glycogen synthase kinase-3: a potential preventive target for prostate cancer managementPhase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Upregulation of CYP17A1 by Sp1-mediated DNA demethylation confers temozolomide resistance through DHEA-mediated protection in glioma.Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.Structure-based optimisation of non-steroidal cytochrome P450 17A1 inhibitors.Pubertal testis volume, age at pubertal onset, and adolescent blood pressure: Evidence from Hong Kong's "Children of 1997" birth cohort.Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.Human Cytochrome CYP17A1: The Structural Basis for Compromised Lyase Activity with 17-Hydroxyprogesterone
P2860
Q26740070-AB7658F2-377F-4764-B04D-D6CC69105F82Q26750620-758F7A6A-EF36-4CC1-B7B7-14FB4B8E515BQ28277042-7883072B-9A19-4E45-B407-C53B0A9301DBQ33845573-D1A38BBD-EF78-4132-B28C-7E6AB803808FQ34525556-C0F0204D-A42A-43CC-962F-40E3153198B2Q35961226-D80AACD7-8A98-4381-A362-7038D126FD76Q36435371-FE43BD17-A628-4083-934F-47B02AA48832Q36580561-6384DCDD-86AC-44D4-A486-1AF121C5B1C9Q38765489-67DBB4E5-95D4-4691-88E9-49EEF7746039Q41098467-E85251E8-12C5-4E17-95A4-4A7F2E5BA499Q41537597-628431E9-2BE8-443C-93A5-66025F049D73Q48185348-DA7ADDCC-6319-4A90-9049-8ED2469E71EFQ53466445-8C448D53-1027-4FF0-A8FD-592896E767ECQ55262957-C090C562-B419-4B02-B709-802386FB1841Q57142928-668FC903-577A-443A-963E-EE8AB7EE66D7
P2860
CYP17A1 inhibitors in castration-resistant prostate cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
CYP17A1 inhibitors in castration-resistant prostate cancer
@ast
CYP17A1 inhibitors in castration-resistant prostate cancer
@en
CYP17A1 inhibitors in castration-resistant prostate cancer
@nl
type
label
CYP17A1 inhibitors in castration-resistant prostate cancer
@ast
CYP17A1 inhibitors in castration-resistant prostate cancer
@en
CYP17A1 inhibitors in castration-resistant prostate cancer
@nl
prefLabel
CYP17A1 inhibitors in castration-resistant prostate cancer
@ast
CYP17A1 inhibitors in castration-resistant prostate cancer
@en
CYP17A1 inhibitors in castration-resistant prostate cancer
@nl
P2093
P2860
P1433
P1476
CYP17A1 inhibitors in castration-resistant prostate cancer
@en
P2093
Dolores J Lamb
Jason R Kovac
Lissette Gomez
P2860
P356
10.1016/J.STEROIDS.2014.12.021
P577
2015-01-03T00:00:00Z